Genflow SIRT6 therapy reduces biological age in aged beagles
Genflow Biosciences reported its SLAB trial met the primary endpoint after treating 24 naturally aged beagles, with treated animals showing a clear, consistent improvement on the Horvath methylation clock versus saline controls. CEO Eric Leire said the result validates the company's centenarian SIRT6 therapy platform and highlighted commercial advantages of their naked DNA delivery, including safety, lower manufacturing costs, no cold-chain requirement, and re-dosing ability. The company is in talks with tier-one animal health firms and will present full methylation-clock and muscle data at the Animal Longevity Summit in Toronto on October 2, while SLAB remains a companion-animal study.
SLAB trial met primary endpoint showing methylation-clock improvement
Context
The company ran a trial in 24 naturally aged beagles that met its main goal. The firm will present full data on October 2. The company is also in discussions with tier-one animal health companies.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked